Kyle Bass Makes First Official Statement On Pharma Strategy to House Committee

1
Kyle Bass Makes First Official Statement On Pharma Strategy to House Committee

Kyle Bass’ Hayman Made First Official Statement on the controversial pharma strategy to a House Committee. The document was first posted earlier today on Harvest.com – see the full document in text and PDF below. April 14, 2015

Statement of J Kyle Bass

Chief Investment Officer, Hayman Capital Management, L.P. U.S. House of Representatives Committee on the Judiciary Hearing: H.R. 9, The “Innovation Act” The Honorable Bob Goodlatte The Honorable John Conyers, Jr.
[drizzle]
Chairman Ranking Member House Judiciary Committee House Judiciary Committee 2138 Rayburn Office Building B-351 Rayburn Office Building Washington, DC 20515 Washington, DC 20515 Dear Chairman Goodlatte and Ranking Member Conyers: We applaud your recent efforts to examine ways to strengthen the patent system. As you continue your work in this area, we strongly urge you to preserve important statutory provisions that provide vital patent protections, while promoting industry competition and consumer relief. Specifically, we believe that the United States Patent and Trademark Office’s (USPTO) Patent Trial and Appeals Board (PTAB) is effectively serving an important purpose as currently structured under the America